EMBO Rep:北京基因组所等揭示维生素C是潜在的肾癌分化治疗小分子

2018-07-11 佚名 北京基因组研究所

维生素C是日常生活中必不可少的营养元素,具有增强抵抗力、抗氧化及美容的功效。自从1970年诺贝尔奖获得者、生物化学家鲍林发表论文认为维生素C可以防治癌症以来,争议的声音也一路伴随,但对维生素C与肿瘤关系的研究从未停止。高剂量的维生素C虽然可以应用在肿瘤治疗中,但是其不稳定性以及高剂量带来的毒性,使得肿瘤治疗中维生素C的开发与利用停滞不前。

维生素C是日常生活中必不可少的营养元素,具有增强抵抗力、抗氧化及美容的功效。自从1970年诺贝尔奖获得者、生物化学家鲍林发表论文认为维生素C可以防治癌症以来,争议的声音也一路伴随,但对维生素C与肿瘤关系的研究从未停止。高剂量的维生素C虽然可以应用在肿瘤治疗中,但是其不稳定性以及高剂量带来的毒性,使得肿瘤治疗中维生素C的开发与利用停滞不前。

近日,中国科学院北京基因组研究所慈维敏研究组与北京大学第一医院周利群研究组合作,利用生理浓度下的低剂量维生素C和其衍生物磷酸酯镁作用于肾癌细胞系,发现低浓度条件下即可有效提升细胞内5-羟甲基胞嘧啶(5hmC)水平,并在一定程度上抑制肿瘤细胞的生长与迁移。维生素C可以通过上调5hmC在透明肾细胞癌中的水平对其进行重编程,进而降低肿瘤恶性程度,且几乎对细胞没有任何特异性损伤,这为寻找肾癌治疗提供了潜在的新策略。相关研究成果以Restoration of 5-hydroxymethylcytosine by ascorbate reduces kidney tumour growth 为题在线发表于EMBO Reports 杂志。

研究采用生理浓度长期作用的策略进行研究,相同的结果也在裸鼠移植瘤、原代透明肾细胞癌病人细胞中得到了印证,5hmC水平升高,伴随着肿瘤细胞的恶性减弱。通过整合长期生理浓度下维生素C及其衍生物作用于肾癌细胞系的hMeDIP-seq测序结果,可以清楚发现5hmC的重编程模式,使其更加倾向于正常细胞。通过用来鉴定超级增强子的CHIP-seq测序进行进一步验证,发现在维生素C及其衍生物长期处理的肾癌细胞中,5hmC上调区主要富集在增强子区域,特别是肾组织相关的超增强子。这些结果证明了维生素C及其衍生物可以在肾癌细胞中诱导5hmC重编程和肾肿瘤细胞中的分化状态。

该研究首次在肾癌中证实了维生素C可以通过促进Tets酶的活性提高5hmC水平,使5hmC重编程至“正常”状态,因而逆转了肾癌细胞的恶性表型,发挥抗肿瘤效果。这一发现不仅为肾癌的治疗提供了新的思路,还为表观遗传学在肿瘤治疗中的重要作用提供了最新依据。目前该研究已申请专利,同时维生素C联合靶向药物治疗透明肾细胞癌的前瞻性研究已在合作单位展开,为利用维生素C及其衍生物在今后的临床治疗中,单独或联合靶向治疗透明肾细胞癌展现了有利前景。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1914671, encodeId=76bb19146e129, content=<a href='/topic/show?id=84d7469559b' target=_blank style='color:#2F92EE;'>#小分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46955, encryptionId=84d7469559b, topicName=小分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Wed Aug 15 14:18:00 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332953, encodeId=0a92332953cf, content=*, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/09/9d6ae4a345db0c5799f866ac5743fbc0.jpg, createdBy=0ba62073690, createdName=GZphD9, createdTime=Fri Jul 20 18:07:21 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332268, encodeId=50e233226837, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jul 17 18:55:49 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331289, encodeId=4cf43312895b, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQplCaQGBmjHytXQqvsuocO2uV2lOAaJibzDafJudKToVfU12LzwArHDb4TSrmU2hk5Qxzc6icoicBK3Dg/0, createdBy=a7901968505, createdName=明心见性, createdTime=Fri Jul 13 10:44:44 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331287, encodeId=e48c33128e4b, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQplCaQGBmjHytXQqvsuocO2uV2lOAaJibzDafJudKToVfU12LzwArHDb4TSrmU2hk5Qxzc6icoicBK3Dg/0, createdBy=a7901968505, createdName=明心见性, createdTime=Fri Jul 13 10:43:25 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
    2018-08-15 宋威
  2. [GetPortalCommentsPageByObjectIdResponse(id=1914671, encodeId=76bb19146e129, content=<a href='/topic/show?id=84d7469559b' target=_blank style='color:#2F92EE;'>#小分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46955, encryptionId=84d7469559b, topicName=小分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Wed Aug 15 14:18:00 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332953, encodeId=0a92332953cf, content=*, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/09/9d6ae4a345db0c5799f866ac5743fbc0.jpg, createdBy=0ba62073690, createdName=GZphD9, createdTime=Fri Jul 20 18:07:21 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332268, encodeId=50e233226837, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jul 17 18:55:49 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331289, encodeId=4cf43312895b, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQplCaQGBmjHytXQqvsuocO2uV2lOAaJibzDafJudKToVfU12LzwArHDb4TSrmU2hk5Qxzc6icoicBK3Dg/0, createdBy=a7901968505, createdName=明心见性, createdTime=Fri Jul 13 10:44:44 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331287, encodeId=e48c33128e4b, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQplCaQGBmjHytXQqvsuocO2uV2lOAaJibzDafJudKToVfU12LzwArHDb4TSrmU2hk5Qxzc6icoicBK3Dg/0, createdBy=a7901968505, createdName=明心见性, createdTime=Fri Jul 13 10:43:25 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
    2018-07-20 GZphD9

    *

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1914671, encodeId=76bb19146e129, content=<a href='/topic/show?id=84d7469559b' target=_blank style='color:#2F92EE;'>#小分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46955, encryptionId=84d7469559b, topicName=小分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Wed Aug 15 14:18:00 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332953, encodeId=0a92332953cf, content=*, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/09/9d6ae4a345db0c5799f866ac5743fbc0.jpg, createdBy=0ba62073690, createdName=GZphD9, createdTime=Fri Jul 20 18:07:21 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332268, encodeId=50e233226837, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jul 17 18:55:49 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331289, encodeId=4cf43312895b, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQplCaQGBmjHytXQqvsuocO2uV2lOAaJibzDafJudKToVfU12LzwArHDb4TSrmU2hk5Qxzc6icoicBK3Dg/0, createdBy=a7901968505, createdName=明心见性, createdTime=Fri Jul 13 10:44:44 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331287, encodeId=e48c33128e4b, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQplCaQGBmjHytXQqvsuocO2uV2lOAaJibzDafJudKToVfU12LzwArHDb4TSrmU2hk5Qxzc6icoicBK3Dg/0, createdBy=a7901968505, createdName=明心见性, createdTime=Fri Jul 13 10:43:25 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
    2018-07-17 wxl882001

    学习一下

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1914671, encodeId=76bb19146e129, content=<a href='/topic/show?id=84d7469559b' target=_blank style='color:#2F92EE;'>#小分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46955, encryptionId=84d7469559b, topicName=小分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Wed Aug 15 14:18:00 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332953, encodeId=0a92332953cf, content=*, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/09/9d6ae4a345db0c5799f866ac5743fbc0.jpg, createdBy=0ba62073690, createdName=GZphD9, createdTime=Fri Jul 20 18:07:21 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332268, encodeId=50e233226837, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jul 17 18:55:49 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331289, encodeId=4cf43312895b, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQplCaQGBmjHytXQqvsuocO2uV2lOAaJibzDafJudKToVfU12LzwArHDb4TSrmU2hk5Qxzc6icoicBK3Dg/0, createdBy=a7901968505, createdName=明心见性, createdTime=Fri Jul 13 10:44:44 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331287, encodeId=e48c33128e4b, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQplCaQGBmjHytXQqvsuocO2uV2lOAaJibzDafJudKToVfU12LzwArHDb4TSrmU2hk5Qxzc6icoicBK3Dg/0, createdBy=a7901968505, createdName=明心见性, createdTime=Fri Jul 13 10:43:25 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
    2018-07-13 明心见性

    ***

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1914671, encodeId=76bb19146e129, content=<a href='/topic/show?id=84d7469559b' target=_blank style='color:#2F92EE;'>#小分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46955, encryptionId=84d7469559b, topicName=小分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Wed Aug 15 14:18:00 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332953, encodeId=0a92332953cf, content=*, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/09/9d6ae4a345db0c5799f866ac5743fbc0.jpg, createdBy=0ba62073690, createdName=GZphD9, createdTime=Fri Jul 20 18:07:21 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332268, encodeId=50e233226837, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jul 17 18:55:49 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331289, encodeId=4cf43312895b, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQplCaQGBmjHytXQqvsuocO2uV2lOAaJibzDafJudKToVfU12LzwArHDb4TSrmU2hk5Qxzc6icoicBK3Dg/0, createdBy=a7901968505, createdName=明心见性, createdTime=Fri Jul 13 10:44:44 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331287, encodeId=e48c33128e4b, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQplCaQGBmjHytXQqvsuocO2uV2lOAaJibzDafJudKToVfU12LzwArHDb4TSrmU2hk5Qxzc6icoicBK3Dg/0, createdBy=a7901968505, createdName=明心见性, createdTime=Fri Jul 13 10:43:25 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
    2018-07-13 明心见性

    ***

    0

相关资讯

Nature:揭示维生素C抗癌新机制——调节干细胞功能

8月21日,Nature期刊上又一篇文章揭示维生素C抗白血病机制,来自美国德州大学儿童西南医学中心(CRI)的研究人员发现,干细胞能吸收异常高水平的抗坏血酸盐(维生素C),然后调节自身功能,从而抑制白血病的发展。

NPJ Precis Oncol:维生素C优先杀死“吃货”肿瘤干细胞!

2018年1月8日海军军医大学东方肝胆外科医院王红阳院士研究团队在《自然》子刊《npj-肿瘤精准医疗》上发表重磅文章,该研究发现维生素C优先杀死肝癌的肿瘤干细胞并改善患者预后。

一个进口药,退出中国

国家药监局发公告,一进口辅助用药申请注销药品批文。

Chest:四种静脉维生素C给药方案在危重症患者的药代动力学分析

由此可见,2g/d的治疗剂量与正常血浆浓度相关,10g/d的治疗剂量与正常偏高的血浆浓度、增加的草酸盐排泄和代谢性碱中毒相关。持续治疗需要预防维生素缺乏症。

Osteoporos Int:增加维C摄入降低髋部骨折风险再添力证

“人老了,骨就松了”,虽然不是所有的老人都会骨质疏松,但这句话从侧面反映了老年人骨质疏松超高的发生率。骨质疏松对老人的危害不可小觑。骨质疏松的悄然入侵犹如 “蚁穴溃堤”,骨折后致死率达20%、致残率高达50% 。

Glia:上海药物所发现维生素C可促进髓鞘再生

中枢神经系统中,髓鞘对神经元功能至关重要。在一些脱髓鞘疾病如多发性硬化(MS)中,免疫系统攻击自身神经系统导致神经髓鞘的破坏和白质损伤,是仅次于创伤的中青年人致残原因,有着“死不了的癌症”之称。现有药物均为免疫抑制剂,只能缓解和减少复发,但对已经造成的神经损伤并无修复作用。发现能促进髓鞘再生和修复的药物作用靶点及小分子化合物是该类疾病研究的新方向。